RxDoctor Payments Data

Jason Woolard, MD

Vascular Surgery · Wichita, KSNPI 1053533349

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 31.0% of the total. 2025 is the largest year on record at $696, 2.3 times the $296 reported in 2019. That places this record below the midpoint for vascular surgery clinicians in KS, where the typical reported total is $5,708.

$3,095in general payments, 2019–2025

Across 118 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$958
  • Johnson & Johnson$433
  • Bard Peripheral Vascular, Inc.$335
  • Abbott$309
  • Medtronic$142
  • Surmodics, Inc.$140
  • plus $779 from 18 others

What the payments were for

  • Food & beverage$3,095100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,095 in reported general payments places this provider in the 35th percentile of 22 vascular surgery providers in Kansas.

See all vascular surgery providers in Kansas

Medicare billing

Part B allowed, 2024
$783,692
Medicare patients
627
Services billed
9,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban30$19,953
EliquisApixaban27$16,943
Prasugrel Hcl131$10,310
BrilintaTicagrelor16$10,176
ClopidogrelClopidogrel Bisulfate468$3,182
Pantoprazole Sodium25$296
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$197
Gabapentin21$81
Warfarin Sodium12$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$433$19,95330 claims
AstraZenecaBrilinta$34$10,17616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 22 vascular surgery providers in Kansas.

Other vascular surgery in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →